PETRI DISH PERSPECTIVES
Send us Fan Mail [https://www.buzzsprout.com/2437458/fan_mail/new] In this episode of Petri Dish Perspectives, we dive into the remarkable story of Illumina, from a small sequencing startup born during the Human Genome Project era to the company that transformed DNA sequencing from a billion-dollar scientific challenge into a routine laboratory tool. We explore how Illumina's sequencing-by-synthesis technology became the gold standard for genomics, enabling everything from cancer research and rare disease diagnosis to population-scale genetic studies. You'll hear how the company built an empire around the idea that reading DNA would become as essential to medicine as blood tests and imaging scans. We also unpack the major milestones that shaped Illumina's rise: the acquisition of Solexa, the launch of revolutionary sequencing platforms, the race to the "$1,000 genome," and the company's ambitious vision for detecting cancer through blood tests. Along the way, we'll examine the controversial Grail acquisition, regulatory battles with the European Union, leadership shakeups, and the strategic decisions that defined one of biotech's most influential companies. From the Human Genome Project to multi-billion-dollar cancer screening ambitions, this is the story of the company that made genomics mainstream. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Illumina #Genomics #DNASequencing #HumanGenomeProject #Grail #CancerDetection #LiquidBiopsy #Biotech #Biotechnology #PrecisionMedicine #GeneticTesting #NextGenerationSequencing #NGS #LifeSciences #HealthcareInnovation #MolecularBiology #CancerResearch #BioTechPodcast #PetriDishPerspectives Support the show [https://www.buzzsprout.com/2437458/support] © 2026 The Perspective Bureau LLC. All rights reserved.
66 Episoder
Kommentarer
0Vær den første til å kommentere
Registrer deg nå og bli medlem av PETRI DISH PERSPECTIVES sitt community!